{"id":"https://openalex.org/W3097286939","doi":"https://doi.org/10.1182/blood-2020-138811","title":"Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome","display_name":"Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097286939","doi":"https://doi.org/10.1182/blood-2020-138811","mag":"3097286939"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-138811","doi":"https://doi.org/10.1182/blood-2020-138811","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-138811","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088077600","display_name":"Jennifer Leigh Crombie","orcid":"https://orcid.org/0000-0003-3445-5129","observed_orcids":["https://orcid.org/0000-0003-3445-5129"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer L. Crombie","raw_affiliation_strings":["Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010499534","display_name":"Svitlana Tyekucheva","orcid":"https://orcid.org/0000-0002-3119-6507","observed_orcids":["https://orcid.org/0000-0002-3119-6507"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svitlana Tyekucheva","raw_affiliation_strings":["Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100690878","display_name":"Zixu Wang","orcid":"https://orcid.org/0000-0002-5974-7366","observed_orcids":["https://orcid.org/0000-0002-5974-7366","https://orcid.org/0000-0001-5297-7858","https://orcid.org/0009-0003-8074-0665"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zixu Wang","raw_affiliation_strings":["Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113981016","display_name":"Alexandra Savell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandra Savell","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111971265","display_name":"Lisa Brennan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Brennan","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059821588","display_name":"Jessica Lowney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Lowney","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057423512","display_name":"Karen Francoeur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154584","display_name":"Verastem (United States)","ror":"https://ror.org/0562yk913","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154584"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Francoeur","raw_affiliation_strings":["Verastem Oncology, Needham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Verastem Oncology, Needham, MA","institution_ids":["https://openalex.org/I4210154584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021158149","display_name":"Josie S. Montegaard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josie Montegaard","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017446407","display_name":"Austin Injae Kim","orcid":"https://orcid.org/0000-0003-1039-0658","observed_orcids":["https://orcid.org/0000-0003-1039-0658","https://orcid.org/0000-0002-9675-9374"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Austin I. Kim","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088343926","display_name":"Jacob Drobnyk Soumerai","orcid":"https://orcid.org/0000-0002-3062-6819","observed_orcids":["https://orcid.org/0000-0002-3062-6819"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob D. Soumerai","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016770040","display_name":"Jon E. Arnason","orcid":"https://orcid.org/0000-0001-9038-7277","observed_orcids":["https://orcid.org/0000-0001-9038-7277"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jon E. Arnason","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087433184","display_name":"Allan Louie Cruz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Allan Louie Cruz","raw_affiliation_strings":["Northern Light Cancer Care, Brewer, ME"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northern Light Cancer Care, Brewer, ME","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055865840","display_name":"Sigrid Berg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sigrid Berg","raw_affiliation_strings":["Northern Light Cancer Care, Brewer, ME"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northern Light Cancer Care, Brewer, ME","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101930428","display_name":"David Christopher Fisher","orcid":"https://orcid.org/0000-0001-6915-8584","observed_orcids":["https://orcid.org/0000-0001-6915-8584"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Fisher","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R Brown","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":2.1662,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.88999404,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"46","last_page":"47"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duvelisib","display_name":"duvelisib","score":0.9940000176429749},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/relapsed-or-refractory-cll","display_name":"relapsed or refractory CLL","score":0.7990000247955322},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9480000138282776},{"id":"https://openalex.org/keywords/richter-syndrome","display_name":"Richter syndrome","score":0.9959999918937683},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6430000066757202},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.718999981880188},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.5139999985694885},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.6269999742507935},{"id":"https://openalex.org/keywords/oral-therapy","display_name":"oral therapy","score":0.32100000977516174},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.578000009059906},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5799999833106995}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.8841907382011414},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5614224076271057},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5292225480079651},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5100125074386597},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46755966544151306},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.3767845928668976},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.32045382261276245},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.30689430236816406},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1515994668006897},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-138811","doi":"https://doi.org/10.1182/blood-2020-138811","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-138811","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310093511","https://openalex.org/W4405047195","https://openalex.org/W2986221576","https://openalex.org/W7140397598","https://openalex.org/W2950535635","https://openalex.org/W2908094279","https://openalex.org/W2994818257","https://openalex.org/W2961546232","https://openalex.org/W2912098275","https://openalex.org/W2405672745"],"abstract_inverted_index":{"Introduction:":[0],"The":[1,428,578],"MURANO":[2],"study":[3,710,809],"demonstrated":[4],"that":[5,53,62],"venetoclax":[6,998],"(VEN)":[7],"plus":[8],"rituximab":[9],"is":[10,37,71,112,196,768],"an":[11,27,38,113,226,831,842,853],"effective":[12],"regimen":[13,795],"for":[14,44,64,74,244,249,274,513,537,547,580,711,770,788,1004],"pts":[15,104,254,347,393,400,453,503,506,510,536,546,565,582,596,620,628,639,665,671,683,705,721,741,750,771],"with":[16,105,120,142,173,220,240,261,264,434,485,496,586,653,666,690,722,754,772],"relapsed/refractory":[17],"(R/R)":[18],"CLL,":[19],"but":[20,728],"included":[21],"2":[22,392,535,545,664,740],"years":[23],"of":[24,41,99,147,225,342,426,430,440,452,488,499,557,635,647,784,805,834,845,856],"treatment":[25],"and":[26,96,108,125,129,163,184,209,258,300,311,319,334,413,445,464,476,508,540,549,563,591,626,658,660,698,700,715,735,739,745,767,786,997],"infusional":[28],"component":[29],"(Seymour":[30],"et":[31,87],"al.,":[32,88],"NEJM,":[33],"2018).":[34],"Duvelisib":[35,996],"(DUV)":[36],"oral":[39,794],"inhibitor":[40],"PI3K-\u03b4/\u03b3":[42],"approved":[43,438,1001],"R/R":[45,106,773],"CLL/SLL":[46,107,581],"after":[47,267,396,568,604,732,780],"two":[48],"prior":[49,278,293,298,301,385,402],"therapies.":[50],"We":[51],"hypothesized":[52],"DUV":[54,68,100,148,160,241,435,512,648,757],"+":[55,69,101,242,649,758],"VEN":[56,70,102,164,195,228,243,260,302,421,431,528,650,759],"would":[57],"lead":[58,145],"to":[59,176,212,230,316,642,702,765,971],"deep":[60],"remissions":[61],"allow":[63],"oral,":[65],"time-limited":[66],"therapy.":[67],"also":[72],"promising":[73],"Richter's":[75],"Syndrome":[76],"(RS),":[77],"as":[78],"this":[79,789,806],"combination":[80,433,1003],"was":[81,161,307,322,387,436,523,529,559,583,729],"synergistic":[82],"in":[83,103,146,329,380,410,420,423,432,450,456,493,534,544,599,655,696,730,1002],"preclinical":[84],"models":[85],"(Iannello":[86],"ASH,":[89],"2019).":[90],"Here":[91],"we":[92],"report":[93],"the":[94,153,223,330,424,437,486,489,500,554,600,633,656,719,814],"safety":[95,763],"preliminary":[97,137],"efficacy":[98],"RS.":[109,755],"Methods:":[110],"This":[111],"ongoing":[114],"investigator-initiated":[115],"phase":[116,154,193,353,411],"I/II":[117],"trial":[118],"(NCT03534323)":[119],"primary":[121],"endpoints:":[122,135],"DLTs,":[123],"MTD,":[124],"RP2D":[126,429],"(phase":[127,132,350],"I)":[128],"CR":[130,588,652,785],"rate":[131],"II).":[133],"Secondary":[134],"PK,":[136],"efficacy.":[138,320],"Pts":[139,219,237,263],"are":[140,238,454,999],"treated":[141,239,349],"a":[143,189,216,494,761],"7-day":[144],"25":[149],"mg":[150,168,171,182,186,200,204,214,232],"BID.":[151],"In":[152,192],"I":[155,351],"trial,":[156],"on":[157,206,215,675,830,841,852],"day":[158,207],"8,":[159],"continued":[162],"initiated":[165],"at":[166,198,327,569,706,813],"10":[167,199,613],"or":[169,202,517,611,614,836,847,858],"20":[170,203],"(inpt)":[172,205],"weekly":[174,217],"ramp-up":[175,229,533],"20/50/100":[177],"(dose":[178],"level":[179],"(DL)1),":[180],"200":[181],"(DL2),":[183],"400":[185,213,231,441],"(DL3)":[187],"using":[188],"3+3":[190],"design.":[191],"II":[194,354],"started":[197,736],"(outpt)":[201],"8":[208],"ramped":[210],"up":[211],"basis.":[218],"RS":[221,357,497,576],"have":[222,621,629,641,677,684,751,778,796],"option":[224],"accelerated":[227],"over":[233],"5":[234],"days":[235],"(inpt).":[236],"12":[245,268,615],"cycles.":[246],"If":[247],"undetectable":[248],"minimal":[250,691],"residual":[251],"disease":[252,693,726],"(uMRD),":[253],"can":[255],"discontinue":[256],"therapy":[257,281,299],"reinitiate":[259],"recurrence.":[262],"persistent":[265],"MRD":[266,321],"cycles":[269,558,734],"continue":[270],"VEN.":[271],"Eligibility":[272],"criteria":[273],"CLL":[275,670,682,714],"pts:":[276],"\u22651":[277],"therapy,":[279,662,738],"requiring":[280],"by":[282,324],"2008":[283,312],"iwCLL":[284,313],"criteria,":[285],"ECOG":[286],"PS":[287],"\u22642,":[288],"adequate":[289],"hematologic/organ":[290],"function,":[291],"no":[292,297],"VEN/DUV.":[294],"For":[295],"RS,":[296,723],">":[303],"1":[304,645,716,724],"yr":[305],"ago":[306],"allowed.":[308],"CTCAE":[309],"v5":[310],"were":[314,348,483,566],"used":[315],"evaluate":[317],"toxicity":[318],"assessed":[323],"8-color":[325],"flow":[326],"10-4":[328],"peripheral":[331],"blood":[332],"(PB)":[333],"bone":[335],"marrow":[336],"(BM)":[337],"(Mayo":[338],"Laboratories).":[339],"Results:":[340],"As":[341],"July":[343],"19,":[344],"2020,":[345],"22":[346],"(n=12),":[352],"(CLL":[355,574],"n=7,":[356],"n=3)).":[358],"Median":[359,384],"age:":[360],"69":[361],"yrs":[362],"(range":[363,389,561],"50-78).":[364],"Del(17p):":[365],"7/22":[366],"(32%),":[367],"TP53":[368],"mutation:":[369],"10/22":[370,382],"(45%),":[371],"del(11q):":[372],"2/22":[373],"(9%),":[374],"unmutated":[375],"IGHV:":[376],"20/22":[377],"(91%),":[378],"mutation":[379],"NOTCH1:":[381],"(45%).":[383],"treatments":[386],"3":[388,606,720,733,749],"1-6),":[390],"including":[391,404,663,775],"who":[394,640,672,777],"relapsed":[395,779],"alloSCT.":[397,703],"15/22":[398],"(68%)":[399],"had":[401,597,651,673,725,742],"BTKi,":[403],"7":[405],"progressors.":[406],"No":[407,515],"DLTs":[408],"occurred":[409],"I,":[412],"PK":[414],"data":[415,552],"showed":[416],"only":[417],"modest":[418],"increase":[419],"exposure":[422],"presence":[425],"DUV.":[427],"dose":[439],"mg.":[442],"Heme":[443],"toxicities":[444,449],"all":[446,753,793],"grade":[447],"non-heme":[448],">25%":[451],"shown":[455],"Table":[457],"1.":[458],"SAEs":[459,482],"included:":[460],"gr3":[461,468],"febrile":[462],"neutropenia":[463,548],"lung":[465],"infection":[466],"(n=2),":[467],"amylase/lipase,":[469],"gastritis,":[470],"arthralgia":[471],"(n=1),":[472,475],"gr2":[473],"colitis":[474],"g5":[477],"hepatic":[478,491],"failure":[479,492],"(n=1).":[480],"All":[481,668],"reversible":[484],"exception":[487],"gr5":[490],"pt":[495,689],"involvement":[498],"liver.":[501],"Eleven":[502],"held,":[504],"9":[505],"dose-reduced,":[507],"6":[509,609],"discontinued":[511,661],"toxicity.":[514],"laboratory":[516],"clinical":[518],"tumor":[519],"lysis":[520],"syndrome":[521],"(TLS)":[522],"observed":[524,799],"per":[525],"Cairo-Bishop":[526],"criteria.":[527],"briefly":[530],"held":[531],"during":[532],"elevated":[538],"LDH":[539],"K,":[541],"then":[542],"later":[543],"thrombocytopenia.":[550],"At":[551],"cutoff,":[553],"median":[555],"number":[556],"7.5":[560],"1-22)":[562],"21":[564],"evaluable":[567],"least":[570],"cycle":[571,605,608,612],"4":[572,627,669],"restaging":[573],"n=18,":[575],"n=3).":[577],"ORR":[579],"94%":[584],"(17/18),":[585],"56%":[587,618],"(primary":[589],"endpt)":[590],"39%":[592],"PR.":[593],"61%":[594],"(11/18)":[595],"uMRD":[598,654,695,787],"PB,":[601],"first":[602],"occurring":[603],"(n=4),":[607],"(n=5),":[610],"(n=1":[616],"each).":[617],"(10/18)":[619],"thus":[622,679],"far":[623],"achieved":[624,694],"BM-uMRD":[625],"not":[630,1000],"yet":[631],"reached":[632],"point":[634],"evaluation.":[636],"58%":[637],"(7/12)":[638],"date":[643,766],"completed":[644],"year":[646],"PB":[657,697],"BM":[659,699],"del(17p).":[667],"progressed":[674],"BTKi":[676],"responded":[678],"far.":[680],"Three":[681],"come":[685],"off":[686,709,747],"study.":[687,748],"One":[688],"nodal":[692],"proceeded":[701],"Two":[704],"DL1":[707],"came":[708,746],"PD":[712,744],"(1":[713],"RS).":[717],"Of":[718],"reduction":[727],"SD":[731],"new":[737],"early":[743],"died,":[752],"Conclusions:":[756],"has":[760],"manageable":[762],"profile":[764],"active":[769],"CLL/SLL,":[774],"those":[776],"BTKi.":[781],"High":[782],"rates":[783],"1-year":[790],"MRD-guided,":[791],"time-limited,":[792],"already":[797],"been":[798],"despite":[800],"short":[801],"follow-up.":[802],"Updated":[803],"results":[804],"actively":[807],"accruing":[808],"will":[810],"be":[811],"presented":[812],"meeting.":[815],"Disclosures":[816],"Crombie:":[817],"Bayer:":[818],"Research":[819,822,868,878,881,884,888,918,925,934,941,946,950,954,958,970,979,986,990],"Funding;":[820,869,879,882,885,926,935,942,947,951,955,959,980,987,991],"Abbvie:":[821],"Funding.":[823,889,919],"Francoeur:Verastem:":[824],"Current":[825],"Employment,":[826],"Other.":[827],"Montegaard:AstraZeneca:":[828],"Membership":[829,840,851],"entity's":[832,843,854],"Board":[833,844,855],"Directors":[835,846,857],"advisory":[837,848,859],"committees;":[838,849],"Pharmacyclics:":[839,948],"Janssen:":[850,981],"committees,":[860],"Other:":[861],"KOL":[862],"lecture":[863],"seires":[864],"guest":[865],"lecturer.":[866],"Soumerai:BostonGene:":[867],"Verastem:":[870,912,917,923],"Consultancy;":[871,873,875,891,913,922,929,931,937,962,964,966,969,975,982],"AstraZeneca:":[872,932],"AbbVie:":[874,930],"TG":[876,910,943],"Therapeutics:":[877,944],"GlaxoSmithKine:":[880],"Genentech/Roche:":[883],"Beigene:":[886],"Consultancy,":[887,924,933,940,945,949,957,985,989],"Arnason:Regeneron:":[890],"Juno:":[892],"Consultancy.":[893,993],"Brown:Janssen,":[894],"Teva:":[895],"Speakers":[896],"Bureau;":[897],"Abbvie,":[898],"Acerta,":[899],"AstraZeneca,":[900],"Beigene,":[901],"Invectys,":[902],"Juno/Celgene,":[903],"Kite,":[904],"Morphosys,":[905],"Novartis,":[906],"Octapharma,":[907],"Pharmacyclics,":[908],"Sunesis,":[909],"Therapeutics,":[911],"Gilead,":[914],"Loxo,":[915],"Sun,":[916],"Davids:Eli":[920],"Lilly:":[921],"Adaptive":[927],"Biotechnologies:":[928],"BeiGene:":[936],"Ascentage":[938],"Pharma:":[939,984],"Surface":[952],"Oncology:":[953],"Novartis:":[956],"Gilead":[960],"Sciences:":[961],"Zentalis:":[963],"Sunesis:":[965],"Syros":[967],"Pharmaceuticals:":[968],"Practice:":[972],"Honoraria;":[973],"Merck:":[974],"Bristol":[976],"Myers":[977],"Squibb:":[978],"MEI":[983],"Genentech:":[988],"Celgene:":[992],"OffLabel":[994],"Disclosure:":[995],"CLL.":[1005]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}